Vertex’s fertility support bid is ‘self-serving,’ HHS saysnews2025-01-15T20:21:52+00:00January 15th, 2025|Endpoints News|
Umoja’s $100M Series C will advance its bid for more convenient cell therapiesnews2025-01-14T16:44:53+00:00January 14th, 2025|Endpoints News|
The embryo editing debate is back, revived by Nature articlenews2025-01-12T17:21:58+00:00January 12th, 2025|Endpoints News|
Tune Therapeutics raises $175M Series B for epigenetic editingnews2025-01-12T13:00:38+00:00January 12th, 2025|Endpoints News|
Shoreline cuts staff as its partnership with Gilead’s Kite is now in fluxnews2025-01-09T21:05:21+00:00January 9th, 2025|Endpoints News|
First-ever gene edit of infant boy leads to apparent curenews2025-01-08T20:57:25+00:00January 8th, 2025|Endpoints News|
Astellas stops developing autologous cell therapy for lymphomanews2025-01-08T18:14:37+00:00January 8th, 2025|Endpoints News|
Vertex signs in vivo gene editing delivery pact for sickle cell and thalassemia with Orna Therapeuticsnews2025-01-07T12:00:02+00:00January 7th, 2025|Endpoints News|
Pfizer ends work on Sangamo’s hemophilia gene therapy, crushing biotech’s hopesnews2024-12-31T16:09:12+00:00December 31st, 2024|Endpoints News|
WuXi AppTec sells cell and gene therapy business to investornews2024-12-26T16:25:08+00:00December 26th, 2024|Endpoints News|
